Experiences with
Ibrutinib2,003 public posts
Dr Sharman begins blogging on relevant ASCO papers
http://www.cll-nhl.com/2013/05/ibrutinib-resistance.html
Neil
Winners And Losers in CLL at ASCO '13 - a marketing strategy consultant's perspective
He covers in particular how the new drugs by Gilead Sciences (idelalisib), Roche (Obinutuzumab - GA101), Infinity Pharmaceuticals (IPI-145), AbbVie (with Roche) (ABT-199), Pharmacyclics and Johnson & Johnson (Ibrutinib) fared in their ASCO presentations and which companies with CLL drug development in
AACR Results Of Single Agent Ibrutinib from Dr. Wiestner of the NIH
Wiestner of the NIH on the one year data on single agent ibrutinib with no other drugs to help in 17p del and > 65 patients, with my commentary: http://bkoffman.blogspot.com/2013/05/ibrutinib-research-from-dr-wiestner-at.html
Bottom line: 94% event free survival at one year. WOW!
Want to take advantage of all our features? Just log in!
or
Infinity Pharmaceuticals to report IPI-145 progress at ASCO 2013
Some company background from Oncology Business Review from February this year comparing Infinity with Pharmalytics (Ibrutinib):
http://obroncology.com/forum/?
Interview with Dr. Adrian Wiestner from the NIH on his Research on Ibrutinib
Wiestner on his research on ibrutinib.
His interviews will be the last from ASH 2012, as I look forward to going to ASCO 2013 and learning and sharing from that. Things are moving fast.
Please take a look at http://bkoffman.blogspot.com and learn from Dr.
Video, Dr. Jennifer Brown.... ibrutinib, idelalisib, and other agents.
Jennifer Brown, MD, PhD, Director, Chronic Lymphocytic Leukemia Center, Dana-Farber Cancer Institute, Assistant Professor of Medicine, Harvard Medical School, discusses the treatment of chronic lymphocytic leukemia with ibrutinib, idelalisib, etc.
http://tinyurl.com/ct7erqs
Clonal evolution, genomic drivers and effects of therapy in CLL
Karl Schwartz of Lymphomation.org has recently raised the important question of whether using drugs like ibrutinib to keep a lid on CLL might give a longer life expectancy than more traditional treatments that are likely to drive clonal evolution.
Pharmacylics have closed their first Phase III Ibrutinib trial with 350 patients
The Wall Street Journal reports that Pharmacylics today announced that the enrollment target of 350 patients for its Phase III study using ibrutinib monotherapy versus ofatumumab in patients with relapsed or refractory CLL/SLL, has been achieved ahead of schedule and enrollments are now officially closed
Pharmacyclics presents positive results of ibrutinib Phase II trial in untreated, relapsed and refractory CLL patients
http://www.news-medical.net/news/20130411/Pharmacyclics-presents-positive-results-of-ibrutinib-Phase-II-trial-in-untreated-relapsed-and-refractory-CLL-patients.aspx
Some quotes:
"Ibrutinib was highly efficacious as a single agent in patients with untreated, relapsed and unresponsive CLL, irrespective
Ibrutinib...FDA 'Breakthrough Therapy' for CLL/SLL ---- 17p deleted only
Food and Drug Administration (FDA) has granted an additional Breakthrough Therapy Designation for the investigational oral agent ibrutinib as monotherapy for the treatment of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) patients with deletion of the short arm of chromosome 17
Dr. Richard Furman InterviewASH 2012
Furman on his experience with ibrutinib and idelasilib (GS-1101), what is known, what isn't, and what the future might hold.
ASH 2012 Interview with Dr. Rick Furman
This is one of my favorite interviews as it tells the story of the phase 1 trials of ibrutinib and idelalisib (CAL 101) by Dr. Furman who was the investigator for them both. See http://bkoffman.blogspot.com
Saying No to Chemo. Part 1
On a personal note, I am continuing to do well on my ibrutinib trial.
Thanks and be well
Brian
ASH 2012 Interviews Part 3 Dr. John Byrd on Ibrutinib
Byrd where he discusses some of the details of what we know about ibrutinib therapy so far.
Interview with Dr. Byrd at ASH 2012 on new medications, especially ibrutinib
Hi,
Dr Byrd is my physician at OSU and arguably has more clinical experience with ibrutinib than anyone else in the world.
On my blog ( http://bkoffman.blogspot.com ) tonight, I posted the first of a 4 part interview done at ASH 2012. It's 10 minutes well spent.